Schizophrenia disorder. paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia ,undiffrentiated schizophrenia
Conditions
Interventions
Intervention 1: citalopram 20mg on the 1st till 7th days, then 40mg on 8th till 42 days. Intervention 2: placebo 1tablet on the 1st till 7th days, then 2 tablets in 8th till 42 days.
Treatment - Drugs
citalopram 20mg on the 1st till 7th days, then 40mg on 8th till 42 days.
placebo 1tablet on the 1st till 7th days, then 2 tablets in 8th till 42 days.
Sponsors
Ahvaz Jundishapur University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Diagnosis of schizophrenia based on DSM-IV TR structured clinical interview by a psychiatrist (faculty member and psychiatry resident), prominent negative Symptoms (PANSS negative score more than 15) , total PANSS score more than 50, no liver disease, no treatment with ECT within 6 months, age between 18 and 70, illness duration at least 1 year. Exclusion criteria: depressive disorder based on DSM-IV TR interview and more than 17 score by Hamilton depression rating scale , MR, schizoaffective, Bipolar disorder, Neurological disorders , severe organic disease for example IHD or CHF, treatment with anti depressants or lithium, deaf mute, substance abuse within 1 month ago (except nicotine and caffeine), use of any other drugs which had interactions with this study, active suicidal or homicidal thoughts, breast feeding or pregnancy, past history of allergy or complications with study medication, EPS, at least 3 months interval with the last dose of long term antipsychotic medication
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive symptoms, negative symptoms, general psychopatology. Timepoint: Days 0, 21, and 42. Method of measurement: PANSS scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Extrapyramidal side effects. Timepoint: Days 0, 21, and 42. Method of measurement: SIMPSON ANGUS SCALE. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Niloufar Khajeddin
Ahvaz Jundishapor University of Medical Sciences
Outcome results
None listed